Rockefeller Capital Management
VRDN icon

Rockefeller Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Rockefeller Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.75K Sell
313
-1,350
-81% -$21.8K ﹤0.01% 4203
2026
Q1 		$32.5K Buy
1,663
+510
+44% +$15.1K ﹤0.01% 3480
2025
Q4 		$35.9K Buy
1,153
+133
+13% +$3.65K ﹤0.01% 3226
2025
Q3 		$22K Buy
+1,020
New +$18.4K ﹤0.01% 3314

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rockefeller Capital Management's VRDN Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Viridian Therapeutics (VRDN) stake by 81% in Q2 2026, selling an estimated $21.8K and leaving 313 shares worth $5.75K. The position accounts for ﹤0.01% of the portfolio, ranked #4203.

Rockefeller Capital Management first reported a position in VRDN in Q3 2025 and has held it in 4 quarters since. The position peaked at $35.9K in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Rockefeller Capital Management held 313 shares of Viridian Therapeutics worth $5.75K as of Q2 2026.
  • Rockefeller Capital Management sold 1,350 Viridian Therapeutics shares in Q2 2026, an estimated $21.8K.
  • Viridian Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4203 holding.
  • Rockefeller Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Viridian Therapeutics position peaked at $35.9K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.